AIG terminates $46.1 billion of credit-default swaps (CDS)

AIG announced on Tuesday that an off balance sheet vehicle created by the Federal Reserve Bank of New York (FRBNY) has purchased $46.1 billion of its toxic collaterised debt obligations (CDOs).

The facility, which was established on November 10, will purchase up to $70 billion of AIG's faltering multi-sector CDOs on which AIG had written CDS contracts, terminating the CDS contracts in the process. Thus far, in addition to the $46.1 billion already moved off of the company's balance sheet, the entity has entered into agreements to purchase an additional $7.4 billion of CDOs from the beleaguered insurer.

According to a spokesperson at AIG, the termination of an additional $11.2 billion of exposure to multi-sector CDOs is pending and dependent on the successful structuring of termination and purchase agreements.

As a part of the original bailout scheme for AIG, the FRBNY hammered out a deal to provide an $85 billion bridge loan in exchange for a 79.9% stake in the company, and also agreed to borrow up to $37.8 billion of the insurer's investment-grade fixed-income securities in return for cash collateral.

The off balance sheet vehicle was set up with $5 billion in equity funding from AIG and $15.1 billion from the FRBNY to purchase CDOs; the FRBNY plans on contributing up to $30 billion in funding to the scheme.

The entity will collect cash flows from the assets that it obtains and pay a distribution to AIG for its equity interest once the principal and interest owed to the FRBNY are paid in full.

See also: Treasury and Fed help AIG lay-off CDO risk
CFO replaced in compensation probe at AIG
US government takes control of AIG

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here